Clinical trials: Rhinitis; Allergic, With Asthma
Perennial Allergic Rhinitis Accompanied by Asthma
Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma
This study aims to compare the efficacy and safety of DW1807 and DW1807-R2 in patients with perennial allergic rhinitis and comorbid asthma.
- Trial name
- NCT07168473
- Testing
- Experimental, Comparator
- Where
- South Korea
- Volunteers
- 274 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Allergic Rhinitis/Rhinoconjunctivitis +-Intermittent Asthma, Sensitization Against Betula Alba (Birch) Pollen
Depigoid Birch 5000 Longterm Study in Adults and Adolescents
Specific immunotherapy for IgE mediated sensitization to birch pollen. Long-term study to assess safety and efficacy of Depigoid(R)Birch 5000 - a modified pollen extract of Betula alba (Birch) - versus placebo.
- Trial name
- NCT01694836
- Testing
- s.c. injection
- Where
- 2 sites in Germany
- Volunteers
- 634 people
- Sponsor
- Leti Pharma GmbH
Asthma, Bronchial, Rhinitis, Allergic, Perennial
Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)
The purpose of this study is to determine the protective effect of an approved medication on asthma and allergic rhinitis (inflammation of the mucous membrane of the nose) upon exposure to cats.
- Trial name
- NCT00092105
- Testing
- MK0476, montelukast sodium
- Volunteers
- 58 people
- Sponsor
- Organon and Co
Asthma and Rhinitis
A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies
GSK2245035 is a highly selective Toll-like receptor 7 (TLR7) agonist that stimulates preferentially the induction of type I interferons.
- Trial name
- NCT01607372
- Testing
- GSK2245035, Type 1 amber glass bottle
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- NCT04898283
- Testing
- 10,000 MG01 +10,000 T521, 30,000 MG01 +10,000 T521
- Where
- 27 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Inmunotek S.L.
Allergic Rhinitis Due to Pollen, Allergic Rhinitis With Asthma
Interaction Between Air Pollution, Pollens and Allergic Rhinitis
Seasonal allergic rhinitis has multiple consequences: sleep disturbances, fatigue, depressed mood, impaired quality of life and productivity, and co-morbid conditions such as asthma, which affects one third of AR patients.
- Trial name
- MISTRAL (NCT05007327)
- Testing
- Exposure to pollen and air pollution
- Where
- France
- Volunteers
- 1,215 people
- Sponsor
- MASK-air SAS
Allergic Asthma, Atopic Dermatitis
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
Phase 1 study to evaluate the safety of MEDI4212.
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Trial name
- NCT01544348
- Testing
- Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous
- Where
- 7 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Type I-Allergy
Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens
Dose-response trial with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)
- Trial name
- NCT00666341
- Testing
- rPhleum
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Allergopharma GmbH & Co. KG
Mild Asthma and Allergic Rhinitis
To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies
The purpose of this study is to examine the safety and effects on the immune system of treatment with GSK2245035 in subjects who suffer from nasal symptoms caused by an allergy to pollen or perennial allergen, with or without…
- Trial name
- NCT01788813
- Testing
- GSK2245035
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Asthma, Allergic Rhinitis
A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329)
Subjects have 8-week with montelukast sodium or comparator drug administration period, 2-week wash-out period and 8-week comparator drug or the drug administration period (with cross-over design) for assessment of the drug…
- Trial name
- NCT00157937
- Testing
- MK0476; montelukast sodium/Duration of Treatment: 16 weeks, Comparator: theophylline ER/Duration of Treatment: 16 weeks
- Volunteers
- 31 people
- Sponsor
- Organon and Co
Asthma, House Dust Mite Allergy
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts
The purpose of this study is to investigate the safety of different doses of sublingual tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma.
- Trial name
- NCT01608243
- Testing
- SLIT tablets of house dust mite allergen extracts
- Where
- France
- Volunteers
- 94 people
- Sponsor
- Stallergenes Greer
Allergic Rhinitis Due to House Dust Mite, Allergic Asthma
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
The study is a single-center, observational design with a 12-month duration. Approximately 100 Chinese adult (18-65 years old) and adolescent (12-17 years old) with moderate to severe house dust mite (HDM) allergic rhinitis (AR)…
- Trial name
- NCT06151938
- Testing
- Standardised allergen extract from house dust mites
- Where
- China
- Volunteers
- 100 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Respiratory Tract Infections
Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels
Primary goal of this non-interventional study is to evaluate the change in level of allergen-specific IgE (EAST class) after allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts and their…
- Conditions
- Rhinitis, Allergic, Respiratory Tract Infections, Allergy, Allergic Asthma
- Trial name
- NCT04389034
- Testing
- Pollinex Quattro with tree- and grass pollen extracts and their mixtures
- Where
- Germany
- Volunteers
- 113 people
- Sponsor
- Allergy Therapeutics
Rhinitis, Allergic, Seasonal, Asthma, Bronchial
An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)
The purpose of this study is to determine the effect of an approved medication on the symptoms of seasonal allergic rhinitis (a seasonal variety of inflammation of the mucous membrane of the nose) in patients who are experiencing…
- Trial name
- NCT00092885
- Testing
- MK0476, montelukast sodium
- Volunteers
- 831 people
- Sponsor
- Organon and Co
Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus
Mite Asthma Pediatric Immunotherapy Trial
The trial aims to demonstrate efficacy of the House Dust Mite SLIT-tablet versus placebo as add-on treatment in children and adolescents (5-17 years) with House Dust Mite allergic asthma based on clinically relevant asthma…
- Conditions
- Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
- Trial name
- MAPIT (NCT03654976)
- Testing
- HDM SLIT-tablet
- Where
- 64 sites in United States, Bulgaria and 7 more
- Volunteers
- 533 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis, Rhinoconjunctivitis
Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma
Safety study of Depigoid vaccine Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), to treat allergic rhinitis or rhinoconjunctivitis with or without asthma.
- Conditions
- Allergic Rhinitis, Rhinoconjunctivitis, Mild Persistent Asthma, Mild Intermittent Asthma
- Trial name
- NCT01591343
- Testing
- Depigoid® (500 DPP/ml)
- Where
- 10 sites in Spain
- Volunteers
- 8 people
- Sponsor
- Laboratorios Leti, S.L.
Asthma
To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)
To evaluate the changes in proinflammatory markers (ltd4 in urine) and eosinophil from peripheral blood after newly initiated montelukast therapy.
- Trial name
- NCT00398151
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 12 Weeks
- Volunteers
- 58 people
- Sponsor
- Organon and Co
Allergy, Rhinitis
Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
Efficacy and Safety from a high-dosed sublingual grass pollen preparation
- Conditions
- Allergy, Rhinitis, Conjunctivitis
- Trial name
- ALLEGRA6 (NCT00623701)
- Testing
- Allerslit forte
- Where
- Germany
- Volunteers
- 126 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinitis Due to Grass Pollens
Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate
This trial is an exploratory randomised, parallel-group, double-blind, placebo- controlled, national, single-centre trial. The trial will be initiated before 2013 grass pollen season and subjects will be randomised in September…
- Trial name
- NCT01854736
- Testing
- Grazax
- Where
- 2 sites in Spain
- Volunteers
- 51 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis/Rhinoconjunctivitis +- Intermittent Asthma, Sensitization Against Phleum Pratense Pollen
Dose Finding Study Depigoid Phleum: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma
Specific immunotherapy for IgE mediated sensitization to grass pollen 4 concentrations of a modified pollen extract of Phleum pratense are applied to find out the optimum dose.
- Conditions
- Allergic Rhinitis/Rhinoconjunctivitis +- Intermittent Asthma, Sensitization Against Phleum Pratense Pollen, Dose-Finding Study
- Trial name
- NCT01634958
- Testing
- Depigoid Phleum
- Where
- 2 sites in Germany
- Volunteers
- 308 people
- Sponsor
- Leti Pharma GmbH